ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, which did not meet key statistical significance markers [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - The lawsuit claims that Altimmune created a false impression of reliable information regarding trial results, while concealing negative data that would impact the topline results [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering funds for investors [4]. - Investors wishing to serve as lead plaintiff must file their motion by October 6, 2025 [1][3]. Group 3: Trial Results - Altimmune's IMPACT Phase 2b MASH trial failed to achieve statistical significance for the primary endpoint related to fibrosis reduction, contrary to the company's previous claims [5]. - The lawsuit alleges that the company concealed higher responses in the placebo group, which negatively affected the trial's topline results [5].